EU GMP Guideline Revision To Impact Chinese Pharmaceutical Export
This article was originally published in PharmAsia News
The European Union has revised its Good Manufacturing Practices guideline to include quality risk management, which will come into effect in July. Analysts note that relevant corporations in China should attach great importance to this development because quality risk management represents the domestic pharmaceutical industry's weakest link. The new demand may impact the export of pharmaceutical preparations as well as medical raw materials. An expert involved in setting China's New GMP Inspectional Guidelines says that the standards follow closely those of the U.S. FDA and EU; thus the guidelines can almost satisfy the new EU GMP requirements. (Click here for more - Chinese Language)
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.